TABLE 1. Studies comparing NAFLD‐related HCC in patients who are noncirrhotic versus patients who are cirrhotic.

Country, study period	No. of patients with HCC	Survival/mortality rate	Recurrence rate (no. of patients) (rate)	(Noncirrhotic NAFLD vs. cirrhotic NAFLD)
Japan, 1991–201883	48 vs. 71	10‐year survival 57.3% vs. 12.9% (p < 0.01)	(34 HCC vs. 49) 5‐year 40.9% vs. 85% (p < 0.01)	>Male sex, >age, >light drinker, >tumor size, >dyslipidemia, <T2D, =HCC histology and differentiation
Sweden, 2004–201784	83 vs. 142	Mortality rate 71% vs. 69% (aHR, 0.93; 95% CI, 0.58–1.51; p = 0.78)		>Age, =male sex, <T2D, =HCC differentiation, >tumor size, <LT, >resection
USA, 2003–201285	36 vs. 47	Mortality rate (aHR, 1.5; 95% CI, 0.57–4; p = 0.4)	21 HCC vs. 37 86% vs. 14% (p < 0.001)	>Age, =male sex, <T2D, =HCC differentiation, >tumor size, >single nodule, <LT, >resection,
Australia, 2000–201286	8 vs. 46			Male sex not assessed, =age, =T2D, =HCC differentiation, >tumor size larger, =median no of HCC, >failed the Milan criteria for LT, >resection
USA and East/Southeast Asia, 2005–201787	470 vs. 770	Survival (HR, 1.14; 95% CI, 0.94–1.37)		>Male sex, =age, <T2D, HCC differentiation not assessed, >tumor size larger in noncirrhotic p < 0.001, >unifocal cancer, >resection, <LT

Note: >significantly higher/larger, <significantly lower/smaller, =no significant difference.

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; LT, liver transplantation; T2D, type 2 diabetes mellitus.